RVG29 is a peptide derived from rabies virus glycoprotein regions known to interact with neural receptors. The sequence contains aromatic and basic residues that support membrane association and receptor recognition. Researchers use it to study peptide-mediated transport across neural barriers. Applications include targeting-motif characterization, peptide-receptor modeling, and delivery-platform development.
RVG29, also known as rabies virus glycoprotein peptide 29, is a synthetic peptide derived from the rabies virus glycoprotein sequence. It is specifically engineered to harness the unique cell-penetrating and receptor-targeting properties of the parent glycoprotein, making it a valuable tool in biomedical research. Characterized by its ability to interact with the nicotinic acetylcholine receptor (nAChR), RVG29 enables targeted delivery across the blood-brain barrier, a significant challenge in central nervous system (CNS) research. Its structure facilitates conjugation with a wide range of molecular cargos, including nucleic acids, proteins, and nanoparticles, thereby expanding its utility in various experimental settings. The peptide's versatility and specificity support innovative approaches in neurobiology, drug delivery, and molecular imaging.
Drug Delivery to the Central Nervous System: RVG29 is widely used to facilitate the transport of therapeutic agents into the brain. By exploiting its high affinity for nAChRs expressed on neuronal cells and at the blood-brain barrier, researchers can conjugate drugs, siRNA, or nanoparticles with the peptide to achieve enhanced brain targeting. This strategy addresses the longstanding obstacle of poor CNS penetration by conventional drugs, enabling more effective delivery of molecular therapies for neurological disorders and brain tumors in preclinical models. The use of RVG29 as a targeting ligand circumvents the need for invasive delivery methods, providing a non-disruptive and efficient alternative for CNS drug research.
Gene Therapy Vector Targeting: The rabies virus glycoprotein-derived peptide is instrumental in gene therapy research, particularly for targeting viral or non-viral vectors to neural tissues. By attaching RVG29 to the surface of gene delivery systems, scientists can direct genetic material specifically to neurons or glial cells. This targeted approach improves transfection efficiency and minimizes off-target effects, which is critical for studying gene function and developing gene-based interventions for neurodegenerative diseases. The specificity of RVG29 for neural cell receptors enables precise delivery, supporting the advancement of safer and more effective gene therapy technologies.
Neuroimaging Probe Development: RVG29's receptor-mediated targeting capability is leveraged in the development of neuroimaging probes. By conjugating imaging agents, such as fluorescent dyes or contrast agents, to the peptide, researchers can achieve enhanced visualization of neural structures and pathological changes in the brain. This application is particularly valuable for tracking disease progression, monitoring therapeutic responses, and mapping brain connectivity in animal models. The peptide's ability to traverse the blood-brain barrier and selectively bind neuronal cells underpins its utility in next-generation imaging methodologies.
Nanoparticle Functionalization: In the realm of nanomedicine, RVG29 is frequently utilized to functionalize nanoparticles for brain-targeted delivery. By decorating the surface of nanoparticles with the peptide, scientists can engineer systems that efficiently cross the blood-brain barrier and accumulate in specific brain regions. This strategy enhances the therapeutic index of nanoparticle-based drug carriers, reduces systemic exposure, and enables localized treatment of CNS conditions. The modularity of RVG29 conjugation techniques allows for the integration of diverse payloads, including small molecules, proteins, and genetic material, supporting a broad spectrum of research applications.
Exosome-Based Delivery Systems: The application of RVG29 extends to the field of extracellular vesicle research, where it is used to modify exosomes for targeted delivery to the brain. By expressing or attaching the peptide on exosome surfaces, researchers can direct these natural nanocarriers to neuronal cells, thereby improving the efficiency of cargo delivery across the blood-brain barrier. This approach is particularly promising for delivering therapeutic RNA, proteins, or small molecules in neurological research. The incorporation of RVG29 enhances the targeting specificity of exosomes, facilitating the study of intercellular communication and the development of advanced delivery platforms for brain research. Through these diverse applications, RVG29 continues to drive innovation in neuroscience, drug delivery, and molecular imaging, providing researchers with a robust tool for overcoming the challenges of brain-targeted research.
1. TMEM16F and dynamins control expansive plasma membrane reservoirs
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
5. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More